through emission and acquisition of new shares, a total of 3.5 million PLN (approx. 1.1 million USD). Proceeds from this round will be used to supplement public financing in two ongoing discovery programs and launch a third program for the development of anti-inflammatory drug candidates.
to co-finance international patent protection for the OAT449 group of compounds. The funding sources is Action 5.4.1 of the Innovative Economy Operational Programme and the value of the contract is approximately 0.4M PLN. “Grants fo innovation”
a contract with the National Center for Research and Developemnt for co-financing of a 7 Miliion PLN, 30-month collaborative preclinical research and development project of a propriatary oncology drug candidate – OAT449. OncoArendi Therapeutics will be the sole owner of the research results of this joint project and plans to bring the preclinical work through GLP toxicology to the pre-ind stage. The funding source is Action 1.3.1 of the Innovative Economy Operational Programme.
drug candidate is simultaneously filed by OncoArendi Therapeutics with the United States Patent and Trademark Office (USPTO) and with the Patent Office of the Republic of Poland.
OncoArendi was successful in securing 1,6M in public financing in an joint application with the Institute of Biophysics and Biochemistry, Polish Academy of Sciences and the International Institute for Molecular and Cell Biology for a project entitled “New drug candidates for targeted therapy of multiple myeloma”.
for a three-year program “New drug candidates for targeted therapy of multiple myeloma”.
The project will run through September 2015.